Nektar Therapeutics (NKTR) Posts Q2 EPS Loss of $0.32, Revenues 60% Y/Y
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $75.92 --0%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
EGRX, MOVE, MDRX, More
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
EGRX, MOVE, MDRX, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.32), $0.01 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $17.3 million versus the consensus estimate of $14.89 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c
- Bio-key International, Inc. (BKYI) Tops Q2 EPS by 24c
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
